GT Biopharma Advances Three TriKE Cancer Drugs with $13M Market Cap
FATE•GT Biopharma’s market capitalization stands at roughly $13 million despite having three TriKE immuno-oncology candidates in human trials. Its lead program GTB-3650 in CD33-positive AML and MDS has advanced through four dose cohorts without dose-limiting toxicities, and Phase 1 dosing of GTB-5550 in B7-H3 solid tumors began in May 2026.
1. Market Capitalization and Pipeline
GT Biopharma carries a market cap of approximately $13 million while operating as a clinical-stage immuno-oncology company. It holds an exclusive worldwide license for its Tri-specific Killer Engager platform from the University of Minnesota and has three candidates actively dosing in human trials.
2. Progress of Lead Program GTB-3650
GTB-3650, targeting relapsed or refractory CD33-positive AML and high-risk MDS, has completed enrollment of Cohort 4 with eight patients and continues to escalate through seven dose cohorts. Safety reviews have shown no dose-limiting toxicities to date, with a meaningful data update expected in the second half of 2026.
3. Initiation of GTB-5550 Solid Tumor Trial
In May 2026, GT Biopharma dosed the first patient in a Phase 1 trial of GTB-5550, which targets B7-H3 expressed on a range of solid tumors including prostate, ovarian, and lung cancers. The program uses subcutaneous dosing for patient convenience and will expand from a prostate-focused escalation into a multi-indication basket trial.
4. Market Opportunity in Immuno-Oncology
The global oncology market is projected to grow from $139 billion in 2025 to $268 billion by 2034, with solid tumors comprising a substantial segment. NK-cell-directed therapies like TriKE are gaining attention for leveraging natural killer cells to attack cancer with potentially fewer side effects, presenting a significant commercial opportunity.
